J.R. Strosberg, J.M. Weber, M. Feldman, D. Coppola, K. Meredith, L.K. Kvols, Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 31, 420–425 (2013). https://doi.org/10.1200/JCO.2012.44.5924

Article  Google Scholar 

M.H. Kulke, L.L. Siu, J.E. Tepper, G. Fisher, D. Jaffe, D.G. Haller, L.M. Ellis, J.K. Benedetti, E.K. Bergsland, T.J. Hobday, E. Van Cutsem, J. Pingpank, K. Oberg, S.J. Cohen, M.C. Posner, J.C. Yao, Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29, 934–943 (2011). https://doi.org/10.1200/JCO.2010.33.2056

Article  CAS  Google Scholar 

Y. Jiao, F. Cao, H. Liu, Radiation-induced Cell Death and Its Mechanisms. Health Phys 123, 376–386 (2022). https://doi.org/10.1097/HP.0000000000001601

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P.L. Kunz, M.H. Kulke, H. Jacene, D. Bushnell, T.M. O’Dorisio, R.P. Baum, H.R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Van Cutsem, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Öberg, M. Lopera Sierra, P. Santoro, T. Thevenet, J.L. Erion, P. Ruszniewski, D. Kwekkeboom, E. Krenning, NETTER-1 Trial Investigators: Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N. Engl. J. Med. 376, 125–135 (2017). https://doi.org/10.1056/NEJMoa1607427

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lutathera | European Medicines Agency, https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera#authorisation-details-section

T. Brabander, W.A. van der Zwan, J.J.M. Teunissen, B.L.R. Kam, R.A. Feelders, W.W. de Herder, C.H.J. van Eijck, G.J.H. Franssen, E.P. Krenning, D.J. Kwekkeboom, Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 23, 4617–4624 (2017). https://doi.org/10.1158/1078-0432.CCR-16-2743.

S. Singh, D. Halperin, S. Myrehaug, K. Herrmann, M. Pavel, P.L. Kunz, B. Chasen, S. Tafuto, S. Lastoria, J. Capdevila, A. García-Burillo, D.-Y. Oh, C. Yoo, T.R. Halfdanarson, S. Falk, I. Folitar, Y. Zhang, P. Aimone, W.W. de Herder, D. Ferone; all the NETTER-2 Trial Investigators, [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet Lond. Engl. 403, 2807–2817 (2024). https://doi.org/10.1016/S0140-6736(24)00701-3

Article  CAS  Google Scholar 

L. Urso, A. Nieri, L. Uccelli, A. Castello, P. Artioli, C. Cittanti, M.C. Marzola, L. Florimonte, M. Castellani, S. Bissoli, F. Porto, A. Boschi, L. Evangelista, M. Bartolomei, Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE. Pharmaceutics 15, 1110 (2023). https://doi.org/10.3390/pharmaceutics15041110

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bartolomei, M., Nieri, A., Uccelli, L., Urso, L.: Considerations on the preliminary results of the NETTER-2 trial: is the glass half full or half empty? Clin. Transl. Imaging. (2024). https://doi.org/10.1007/s40336-024-00636-1

J.W.M. Lenders, Q.-Y. Duh, G. Eisenhofer, A.-P. Gimenez-Roqueplo, S.K.G. Grebe, M.H. Murad, M. Naruse, K. Pacak, W.F. Young, Endocrine Society: Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915–1942 (2014). https://doi.org/10.1210/jc.2014-1498

Article  CAS  PubMed  Google Scholar 

A.K.-Y. Lam, Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr. Pathol. 28, 213–227 (2017). https://doi.org/10.1007/s12022-017-9484-5

Article  PubMed  Google Scholar 

P.-F. Plouin, P. Fitzgerald, T. Rich, M. Ayala-Ramirez, N.D. Perrier, E. Baudin, C. Jimenez, Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm. Metab. Res. Horm. Stoffwechselforschung Horm. Metab. 44, 390–399 (2012). https://doi.org/10.1055/s-0031-1299707

Article  CAS  Google Scholar 

O. Hamidi, Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management. Curr. Opin. Endocrinol. Diabetes Obes. 26, 146–154 (2019). https://doi.org/10.1097/MED.0000000000000476

Article  PubMed  Google Scholar 

A. Roman-Gonzalez, S. Zhou, M. Ayala-Ramirez, C. Shen, S.G. Waguespack, M.A. Habra, J.A. Karam, N. Perrier, C.G. Wood, C. Jimenez, Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann. Surg. 268, 172–178 (2018). https://doi.org/10.1097/SLA.0000000000002195

Article  PubMed  Google Scholar 

C. Jungels, I. Karfis, 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma. Curr. Opin. Oncol. 33, 33–39 (2021). https://doi.org/10.1097/CCO.0000000000000691

Article  CAS  PubMed  Google Scholar 

J.C. Sisson, B. Shapiro, W.H. Beierwaltes, Scintigraphy with I-131 MIBG as an aid to the treatment of pheochromocytomas in patients with the multiple endocrine neoplasia type 2 syndromes. Henry Ford Hosp. Med. J. 32, 254–261 (1984)

CAS  PubMed  Google Scholar 

J. Treuner, T. Klingebiel, U. Feine, J. Buck, G. Bruchelt, R. Dopfer, R. Girgert, W. Müller-Schauenburg, J. Meinke, W. Kaiser, Clinical experiences in the treatment of neuroblastoma with 131I-metaiodobenzylguanidine. Pediatr. Hematol. Oncol. 3, 205–216 (1986). https://doi.org/10.3109/08880018609031220

Article  CAS  PubMed  Google Scholar 

D. Taïeb, R.J. Hicks, E. Hindié, B.A. Guillet, A. Avram, P. Ghedini, H.J. Timmers, A.T. Scott, S. Elojeimy, D. Rubello, I.J. Virgolini, S. Fanti, S. Balogova, N. Pandit-Taskar, K. Pacak, European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging. 46, 2112–2137 (2019). https://doi.org/10.1007/s00259-019-04398-1

Article  PubMed  PubMed Central  Google Scholar 

S. Vöö, J. Bucerius, F.M. Mottaghy, I-131-MIBG therapies. Methods San Diego Calif 55, 238–245 (2011). https://doi.org/10.1016/j.ymeth.2011.10.006

Article  CAS  PubMed  Google Scholar 

I.Y.F. Mak, A.R. Hayes, B. Khoo, A. Grossman, Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma. Neuroendocrinology 109, 287–298 (2019). https://doi.org/10.1159/000499497

Article  CAS  PubMed  Google Scholar 

D.A. Pryma, B.B. Chin, R.B. Noto, J.S. Dillon, S. Perkins, L. Solnes, L. Kostakoglu, A.N. Serafini, M.H. Pampaloni, J. Jensen, T. Armor, T. Lin, T. White, N. Stambler, S. Apfel, V.A. DiPippo, S. Mahmood, V. Wong, C. Jimenez, Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 60, 623–630 (2019). https://doi.org/10.2967/jnumed.118.217463

Article  CAS  Google Scholar 

I. Janssen, E.M. Blanchet, K. Adams, C.C. Chen, C.M. Millo, P. Herscovitch, D. Taieb, E. Kebebew, H. Lehnert, A.T. Fojo, K. Pacak, Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 21, 3888–3895 (2015). https://doi.org/10.1158/1078-0432.CCR-14-2751

Article  CAS  Google Scholar 

M.S. Hofman, W.F.E. Lau, R.J. Hicks, Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiogr. Rev. Publ. Radiol. Soc. N. Am. Inc. 35, 500–516 (2015). https://doi.org/10.1148/rg.352140164

Article  Google Scholar 

M. van Essen, E.P. Krenning, P.P. Kooij, W.H. Bakker, R.A. Feelders, W.W. de Herder, J.G. Wolbers, D.J. Kwekkeboom, Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 47, 1599–1606 (2006)

N.D. Niemeijer, G. Alblas, L.T. van Hulsteijn, O.M. Dekkers, E.P.M. Corssmit, Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin. Endocrinol. 81, 642–651 (2014). https://doi.org/10.1111/cen.12542

Article  CAS  Google Scholar 

G. Kong, S. Grozinsky-Glasberg, M.S. Hofman, J. Callahan, A. Meirovitz, O. Maimon, D.A. Pattison, D.J. Gross, R.J. Hicks, Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. J. Clin. Endocrinol. Metab. 102, 3278–3287 (2017). https://doi.org/10.1210/jc.2017-00816

Article  PubMed  Google Scholar 

S. Severi, A. Bongiovanni, M. Ferrara, S. Nicolini, F. Di Mauro, M. Sansovini, I. Lolli, E. Tardelli, C. Cittanti, V. Di Iorio, E. Mezzenga, E. Scarpi, T. Ibrahim, G. Paganelli, S. Zovato, Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. ESMO Open 6, 100171 (2021). https://doi.org/10.1016/j.esmoop.2021.100171

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Prado-Wohlwend, M.I. Del Olmo-García, P. Bello-Arques, J.F. Merino-Torres, [177Lu]Lu-DOTA-TATE and [131I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center. Front. Endocrinol. 13, 778322 (2022). https://doi.org/10.3389/fendo.2022.778322

Article  Google Scholar 

S. Satapathy, B.R. Mittal, A. Bhansali, Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis. Clin. Endocrinol. 91, 718–727 (2019). https://doi.org/10.1111/cen.14106

Article  Google Scholar 

L. Urso, S. Panareo, A. Castello, M.R. Ambrosio, M.C. Zatelli, M. Caracciolo, E. Tonini, G. Valpiani, A. Boschi, L. Uccelli, C. Cittanti, M. Bartolomei, Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial. Pharmaceutics 14, 2009 (2022). https://doi.org/10.3390/pharmaceutics14102009

Article